Probleme beim Einloggen
Billy Waterman Biodefense Market worth $17bn by 2024
Request Sample Copy of this Report : http://bit.ly/2Na0uVO
Key Industry Trends and Driving Factors :
Increasing threat of bioterrorism and presence of favorable government initiatives against bio-terrorism are significant factors that will drive the global market in the coming years. Several government laws such as Project Bioshield provides countries with countermeasures against any chemical, biological, radiological or nuclear (CBRN) attack.
Regulatory bodies such as Biomedical Advanced Research and Development Authority (BARDA), National Institute of Allergy and Infectious Diseases (NIAID) encourage funding for development of therapeutic products.
Project BioShield ensures the availability of ‘next generation’ medical countermeasures against anthrax, smallpox and other CBRN agents. The primary objectives of the project include creation of funding authority to develop next generation countermeasures, design new and speedy R&D programs, and development of a speedy authorization body like FDA to permit effective use of treatments in emergency.
Key insights from the report include:
Global biodefense market size was driven by the anthrax segment, which was USD 3 billion in 2015 and is anticipated to grow at 5% from 2016 to 2024.
Revenue growth will be propelled by smallpox segment that is set to increase at 7.4% CAGR estimations to exceed USD 4 billion by 2024.
Eminent companies entered into contracts with the government for addressing a range of healthcare, scientific, national security and international security issues, which has led to high U.S. biodefense market share.
European countries of Germany and UK of biodefense market are set to witness lucrative growth rate due to designated funding policies in place.
Companies operating in the industry include Xoma Corporation, Emergent Biosolutions, Cleveland BioLabs, Nanotherapeutics, SIGA Technologies, etc. Presence of extensive product portfolio and strong pipeline will contribute to profitability.
Rahul AGRAWAL Ein beispielloser Blick in die Zukunft der Krebs-API-Industrie - Trends 2018
Holen Sie sich das komplette Brancheninformations-PDF hier - http://bit.ly/Cancer-API
Der globale Krebs-API-Markt wird wahrscheinlich im Berichtszeitraum in einem gesunden Tempo expandieren. Mehrere Faktoren wurden identifiziert, die derzeit das Marktwachstum beeinflussen. Dazu gehören die wachsende Nachfrage nach niedermolekularen Wirkstoffen, zunehmende Trends bei der Offshore-Herstellung pharmazeutischer Produkte, eine erhöhte Prävalenz von Krebs und die Ankunft neuer pharmazeutischer Wirkstoffe (API). Darüber hinaus ebnet die Einführung von Smart Healthcare den Weg für neue APIs einschließlich Krebs-APIs.
Zweifellos werden die sich bietenden Chancen anschaulicher, aber die Herausforderungen bleiben für den Markt gewaltig. Es ist noch ein langer Weg, bis die erwarteten Heilungsraten von Krebsmedikamenten und Krebsbehandlungen erreicht werden, geschweige denn die Nebenwirkungen, die sie haben. Die Entwickler verlagern ihren Fokus jedoch auf natürliche Verbindungen, um das Risiko unerwünschter Reaktionen zu reduzieren, was wiederum ihre Akzeptanz weltweit erhöhen wird. Der Umfang der Diskussion umfasst fünf Hauptkategorien von API-Molekülen, nämlich Tinib, Rafenib, Parib, Lisib, Degib und Ciclib.
Billy Waterman Advanced Wound Care Market size to exceed USD 13 bn by 2024
Request Sample Copy of this Report : http://bit.ly/2MVcCtC
Growth Factors:
Increasing incidences of chronic diseases such as diabetes, obesity and consequent rise in incidences of chronic wounds will drive advanced wound care market over the forecast period. Impaired or delayed wound healing in chronic diseases as well as after surgical procedures poses serious threat to patients and put them at risk of infection, amputation and even death.
As a result, unmet need of superior healing technologies that enable rapid healing is prevailing in the global wound care industry.
Rising geriatric population base that are at high risk of developing chronic wounds will support the demand of advanced wound care products. This rising patient pool suffering from chronic wounds causes significant cost burden on healthcare systems across the globe.
The existing and rising cost burden of these chronic wounds is predicted to drive the investments in advance wound care technology rendering significant positive impact on industry growth. However, prohibitive cost of advance wound care products that often undermines treatment affordability will impede the industry growth in foreseeable future.
Advanced Wound Care Market, by Product, 2013-2024, (USD million) :
Wound Dressings :
-Antimicrobial Dressings
-Alginate Dressings
-Hydrogel Dressings
-Foam Dressings
-Film Dressings
-Hydrocolloidal Dressings
Wound Therapy Devices :
-Negative Pressure Wound Therapy Systems
-Pressure Relief Devices
-Electrostimulation Devices
-Oxygen and Hyperbaric Oxygen Equipment
Competitive Market Share :
Some of the key players in global advanced wound care market are Medtronic, Smith and Nephew, 3M, Derma Sciences, Acelity, Mölnlycke, Integra LifeSciences Corporation, Organogenesis, MPM Medical, Human Biosciences, Hollister Incorporated, Beiersdorf global, HARTMANN International, and Medline Industries. Inc.
Key strategies adopted by most of the key industry players include, acquisitions, mergers, distribution agreements and innovative product launch to strengthen product portfolio and garner higher market share. For instance, in July 2018, Mölnlycke completed acquisition of SastoMed GmbH, a German wound care company to expand its product portfolio and offerings in advanced wound care market.
Billy Waterman Biosensors Market statistics and research analysis released in latest report
Request sample copy @ https://bit.ly/2wKMFCf
Biosensors Market size was valued over USD 17 billion in 2017 and is expected to witness growth of around 8% CAGR from 2018 to 2024.
Increasing prevalence of diabetes has influenced industry growth positively. As per WHO, number of diabetic patients globally in 2014 were around 422 million that have escalated demand for glucose biosensors. Growing awareness regarding diabetes self-management has enabled integration of advanced technology in the glucometers driving the market growth. For instance, newly developed glucometers have embedded microchips that allows accurate and quick detection of sugar levels at home. Rising preference for such technology variant diabetic biosensors have boosted the industry growth significantly.
Salah Sohbi FDA, Root Cause Analysis und Kepner-Tregoe
Wie lösen Sie Probleme in der Pharmaproduktion? z. B. Qualitäts- und Produktionsabweichungen bei der Fertigung fester Arzneiformen (Tabletten, Kapseln, Pellets, Retardformen. u.v.m.)?
Die Kepner-Tregoe Methodik wird aktuell bei der FDA als Root Cause Analyse Methode empfohlen (S. 15).
Unsere Workshopempfehlung "Problemlösung und Entscheidungsfindung"
http://kepner-tregoe.de/workshops/our-workshops/
http://www.fdanews.com

Moderatoren

Infos zu den Moderatoren

Über die Gruppe "Pharma Outsourcing & Business Development"

  • Gegründet: 17.01.2011
  • Mitglieder: 1.124
  • Sichtbarkeit: offen
  • Beiträge: 746
  • Kommentare: 22